News | Hypertension | February 13, 2017

FDA Grants Expedited Access Pathway for MobiusHD to Treat Resistant Hypertension

EAP program designed to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments

February 13, 2017 — Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD device for the treatment of resistant hypertension.

VDI was also one of only nine companies chosen for the FDA’s Early Feasibility Study Investigational Device Exemptions (IDE) Pilot Program in 2012. The Pilot Program enables companies to conduct smaller-scale studies under the guidance of the FDA in the United States in order to meet the requirements for an earlier pathway toward approval.

The EAP program is a focused initiative, recently launched by FDA, to significantly accelerate access for U.S. patients and their physicians to innovative medical treatments. The program was designed for certain medical devices that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases or conditions, such as resistant hypertension, that may be subject to premarket approval applications.

The MobiusHD System, a minimally-invasive system for the treatment of resistant hypertension, capitalizes on the ability of the body’s baroreceptor mechanism to regulate blood pressure. Baroreceptors are receptors located in the carotid artery that sense blood pressure and relay that information to the brain. The MobiusHD implant is designed to amplify the signals received by the surrounding arterial baroreceptors, and thereby amplify the body’s natural response to lower blood pressure through vasodilation.

“Among the benefits of the technology are that it may reduce ambulatory blood pressure in resistant hypertension patients who have not benefited from other device or drug based treatments,” said Prof. Brian Williams, co-principal investigator of the CALM II worldwide clinical trial, and NIHR University College London Hospitals Biomedical Research Centre Director. “The Mobius HD technology may provide an important solution for those patients. We are enthusiastic about the product’s potential as we have seen tremendous results in early studies in the U.S. and Europe.”

“In clinical practice, we regularly observe that despite multiple treatment modalities, many patients are still not responding adequately to therapy, whether it be lifestyle changes, multiple drug therapy, or the combination of each. This lack of response significantly increases their risk of further complications,” said Gregg Stone, M.D., co-principal investigator of the CALM II worldwide clinical trial and director of cardiovascular research and education for Columbia University Medical Center/New York-Presbyterian Hospital and co-director of medical research and education at the Cardiovascular Research Foundation.

“The EAP Designation for the MobiusHD device comes at a critical time for hypertension physicians, who are actively looking for treatment options for patients who are not adequately managed with current guideline-directed therapies,” said George Bakris, M.D., chairman of the worldwide CALM II clinical trial hypertension committee and director, ASH Comprehensive Hypertension Center, The University of Chicago School of Medicine.

For more information: www.vasculardynamics.com

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init